Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KLF5
REST API REST API
Homo sapiens
KLF5 is differentially expressed in 305 experiments: 177 organism parts: lung, prostate, ... (175 more);, 217 disease states: normal, control, ... (215 more);, 89 cell types 508 cell lines 49 compound treatments and 74 other conditions.
Synonyms IKLF, BTEB2, CKLF
Orthologs Klf5 (Mus musculus)   klf5a (Danio rerio)   KLF5 (Gallus gallus)   A4IFB2_BOVIN (Bos taurus)   Klf5 (Rattus norvegicus)   Q4H3A0_CIOIN (Ciona intestinalis)   klf5 (Xenopus laevis)   KLF5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, DNA binding, protein binding, regulation of transcription, DNA-dependent, intracellular, transcription, DNA-dependent, positive regulation of cell proliferation, metal ion binding, nucleic acid binding, transcription from RNA polymerase II promoter, nucleus, positive regulation of transcription, DNA-dependent, zinc ion binding, microvillus assembly, sequence-specific DNA binding transcription factor activity
InterPro Term Znf_C2H2-like, Znf_C2H2
UniProt Accession A2TJX0, Q13887, Q5T6X2, B4DL96
Search EB-eye ENSG00000102554
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (39 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
SW480
3
E-MTAB-37, E-MEXP-1014, E-GEOD-18005
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
BT-474
2
E-GEOD-3529, E-GEOD-5823
502 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21909, ... (50 experiments)

Factor Value U/D Experiments
stromal cell
3
E-MEXP-2034, E-MEXP-1327, E-GEOD-1460
CD8+ T cell
2
E-GEOD-6740, E-AFMX-5
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
fibroblast
1
2
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
centroblast
1
E-GEOD-15271
monolayer
1
E-GEOD-4219
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-16363, E-MTAB-680, E-MTAB-62, ... (53 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
Duchenne muscular dystrophy
2
E-GEOD-1007, E-GEOD-3307
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
211 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-GEOD-5824, ... (33 experiments)

Factor Value U/D Experiments
none
5
10
E-TABM-868, E-MEXP-1230, E-GEOD-7708, E-GEOD-5824, E-MEXP-1958, ... (15 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
nickel(II) chloride hexahydrate
1
E-GEOD-6907
chloroguine
1
E-GEOD-5418
valproic acid
1
E-GEOD-1615
CNOT7+CNOT8
1
E-MEXP-2218
43 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1140, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-GEOD-4667

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-147, E-GEOD-21887

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-GEOD-361, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-TABM-868, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-1648, E-TABM-118, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-9723, E-MEXP-561, E-GEOD-980, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-MEXP-1412, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-12293, E-GEOD-7307, E-GEOD-16363, E-GEOD-1295 ... (5 experiments)

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Processing time: 0.321 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM